Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A
- 1 July 1989
- journal article
- research article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 281 (4) , 219-226
- https://doi.org/10.1007/bf00431054
Abstract
Since cyclosporin A (CsA) is an immuno-suppressive agent, its beneficial effect in psoriasis suggests that immune cells may play a role in the pathogenesis and resolution of psoriasis. To determine early effects of CsA in psoriasis, we quantitated immune cells using double immunofluorescence microscopy on biopsy specimens obtained prior to therapy and after 3,7, and 14 days of CsA therapy. CsA therapy resulted in significant reductions in the absolute number of immune cells (including T cells, monocytes/macrophages, and antigen presenting cells) contained within psoriatic skin. The effect was rapid, with over one-half of the reduction in the density of HLe1+ (human leukocyte antigen-1 positive or bone marrow derived) cells, including T cells, activated T cells, monocytes, and Langerhans cells (LCs), occurring within 3 days. Despite the overall reduction in the numbers of immunocytes in the skin, the proportion of T cells, Langerhans cells, and monocytes in relation to the total number of immune cells was unchanged with therapy, reflecting equally proportional losses of each subtype. Dermal CD1+DR+ cells (putative Langerhans cells), which are not found in normal skin but are present in lesional psoriasis skin, were virtually cleared from the papillary dermis after CsA therapy. Although absolute numbers of epidermal Langerhans cells, defined as cells expressing both CD1 (T6) and DR molecules (CD1+DR+), were also reduced after CsA, epidermal non-Langerhans CD1-DR+ cells (macrophages, activated T cells, DR- keratinocytes) demonstrated a proportionally greater decrease, with the ratio of CD1+DR+ Langerhans cells/non-Langerhans CD1-DR+ epidermal cells changing from a mean of 0.82 at baseline to 1.92 at day 14. Thus, early in the course of therapy, CsA appears to be effective at clearing CD1-DR+ cells while leaving LC relatively intact in the epidermis.Keywords
This publication has 33 references indexed in Scilit:
- Defined In Situ Enumeration of T6 and HLA-DR Expressing Epidermal Langerhans Cells: Morphologic and Methodologic AspectsJournal of Investigative Dermatology, 1986
- Different In Situ Distribution Patterns of Dendritic Cells Having Langerhans (T6+) and Interdigitating (RFD1+) Cell Immunophenotype in Psoriasis, Atopic Dermatitis, and Other Inflammatory DermatosesJournal of Investigative Dermatology, 1986
- Antigen-Presenting OKM5+ Melanophages Appear in Human Epidermis After Ultraviolet RadiationJournal of Investigative Dermatology, 1986
- The distribution and quantification of the Langerhans cell in normal human epidermisClinical and Experimental Dermatology, 1986
- Fluorescence Microscopic and Flow Cytometric Analysis of Bone Marrow-Derived Cells in Human Epidermis: A Search for the Human Analogue of the Murine Dendritic Thy-1+ Epidermal CellJournal of Investigative Dermatology, 1985
- The Effects of Topical Treatment with Steroids or Dithranol on Epidermal T Lymphocytes and Dendritic Cells in PsoriasisScandinavian Journal of Immunology, 1985
- An assessment of Langerhans cell quantification in tissue sectionsJournal of the American Academy of Dermatology, 1984
- Langerhans Cells in Skin from Patients with Psoriasis: Quantitative and Qualitative Study of T6 and HLA-DR Antigen-Expressing Cells and Changes with Aromatic Retinoid AdministrationJournal of Investigative Dermatology, 1983
- Expression of HLA-DR Antigen in Skin from Patients with PsoriasisJournal of Investigative Dermatology, 1982
- Lymphocytes in the normal epidermis of the rat and of manThe Anatomical Record, 1949